ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 581,34
-0,67%
Dow Jones
40 211,72
0,53%
DAX
18 503,97
-0,52%
Brent Oil
83,67
-0,79%
Bitcoin
63 191,71
-2,56%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
09/05/200614h00PR Newswire (US)Allos Therapeutics Reports First Quarter 2006 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/04/200614h00PR Newswire (US)Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 TrialNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/03/200614h00PR Newswire (US)Allos Therapeutics Appoints Paul L. Berns as President and CEONASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/03/200614h00PR Newswire (US)Allos Therapeutics Reports 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/03/200614h00PR Newswire (US)Allos Therapeutics to Present at the 2006 Cowen Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
14/02/200614h00PR Newswire (US)Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in MoNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/02/200614h00PR Newswire (US)Allos Therapeutics to Present at the 2006 BIO CEO & Investor ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/01/200601h22PR Newswire (US)Allos Therapeutics Announces CEO Succession PlansNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/01/200614h00PR Newswire (US)Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases OriNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/12/200514h02PR Newswire (US)Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating FNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/12/200514h00PR Newswire (US)PDX Shows Promising Activity in Patients With Resistant T-Cell LymphomasNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/11/200514h02PR Newswire (US)Allos Therapeutics Appoints Timothy P. Lynch to Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/11/200514h01PR Newswire (US)Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/11/200514h00PR Newswire (US)Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/11/200514h02PR Newswire (US)Allos Therapeutics Reports Third Quarter 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/11/200514h02PR Newswire (US)Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/10/200518h02PR Newswire (US)Allos Therapeutics Announces Dismissal of Securities Class Action LawsuitNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/10/200515h01PR Newswire (US)Allos Therapeutics to Present at the 2005 BIO Investor ForumNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/10/200500h06PR Newswire (US)Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/09/200515h00PR Newswire (US)Allos Therapeutics to Present at the UBS Global Life Sciences ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/09/200515h02PR Newswire (US)Allos Therapeutics to Present at the Bear Stearns Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/200515h00PR Newswire (US)Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients ReceiNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/08/200515h01PR Newswire (US)Allos Therapeutics Reports Second Quarter 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/06/200521h28PR Newswire (US)Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug SubstanceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/05/200500h46PR Newswire (US)Allos Therapeutics Announces Stockholder Approval of Share ExchangeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/05/200515h00PR Newswire (US)Allos Therapeutics to Present at the Needham & Company Biotechnology ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/200515h01PR Newswire (US)Allos Therapeutics Reports First Quarter 2005 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/03/200512h00PR Newswire (US)Allos Therapeutics to Present at SG Cowen's Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/200512h02PR Newswire (US)Allos Therapeutics Reports 2004 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/200512h00PR Newswire (US)Allos Therapeutics Announces $50 Million FinancingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

NYSE
DIS
Walt Disney
EU
EN
Bouygues
NYSE
JPM
JP Morgan Chase
EU
AF
Air FranceKLM
EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
GOOGL
Alphabet
EU
HO
Thales
EU
PX4
SBF 120
EU
BEL20
Bel 20
NYSE
NKE
Nike
NYSE
MCD
McDonalds
EU
CAP
Capgemini
EU
BN
Danone
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés